NanoVation Therapeutics™’s Post

 ✨ The B6-HATXN3 mouse model is a significant advancement in SCA3 research, offering crucial insights into the genetic mutations causing spinocerebellar ataxia type 3. ✅ This model closely mirrors SCA3's pathology, aiding in preclinical studies, biomarker identification, and therapy evaluation. ✅ The TurboKnockout technology enhances its versatility for genetic diversity representation in patients, supporting drug screening and pharmacological studies. Cyagen's introduction of the B6-HATXN3 model highlights their commitment to medical research progress in SCA3 treatment. Learn more about this mouse model here: https://lnkd.in/d9iRFQmr #mousemodels #preclinicalresearch #research #science #biotech #biotechnology #genetherapy

Adenine base editors, such as ABE7.10, enable programmable C•G to T•A point mutations, but editing efficiencies can be low at challenging loci in primary human cells. 🧬 Discover how Beam Therapeutics leveraged DNA variant libraries of adenine base editors, synthesized by Ranomics, to evolve ABE7.10 into the ABE8s with superior editing performance 👉 https://lnkd.in/gAJCq7TJ #beamtherapeutics #crisprcas9 #geneediting #genetherapy #geneticengineering #dna

MicroRNA (miRNA) is a class of non-coding single-stranded RNA molecules with a length of about 22 nucleotides encoded by endogenous genes. They play an important role in the process of cell differentiation, biological development, and disease development. With in-depth research on the mechanism of miRNA, miRNA is expected to provide new ideas for diagnosis and drug discovery and development. GenCefe's experienced oligo synthesis technology team has developed various miRNA mimics for gain-of-function studies and inhibitors for loss-of-function studies, with different options for both in vitro and in vivo experiments. Get a free quote NOW: oligo@gencefebio.com #rnasynthesis #miRNA #microRNA #miRNAinhibitor #miRNAmimic

MicroRNA (miRNA) is a class of non-coding single-stranded RNA molecules with a length of about 22 nucleotides encoded by endogenous genes. They play an important role in the process of cell differentiation, biological development, and disease development. With in-depth research on the mechanism of miRNA, miRNA is expected to provide new ideas for diagnosis and drug discovery and development. GenCefe's experienced oligo synthesis technology team has developed various miRNA mimics for gain-of-function studies and inhibitors for loss-of-function studies, with different options for both in vitro and in vivo experiments. Get a free quote NOW: oligo@gencefebio.com #rnasynthesis #miRNA #microRNA #miRNAinhibitor #miRNAmimic

MicroRNA (miRNA) is a class of non-coding single-stranded RNA molecules with a length of about 22 nucleotides encoded by endogenous genes. They play an important role in the process of cell differentiation, biological development, and disease development. With in-depth research on the mechanism of miRNA, miRNA is expected to provide new ideas for diagnosis and drug discovery and development. #MicroRNA #miRNA #RNAsynthesis #syntheticbiology #Biotech

New results demonstrate the power of the structure-guided fragment-based approach for identifying binders for classes of proteins that are otherwise generally considered intractable for drug discovery. Our new preprint highlights the direct targeting of brachyury, a historically undruggable target, by small molecules. Read more: https://lnkd.in/g72ebV86

It is indeed an honour to present our poster on the 15th Wädenswil Day of Life Sciences: 6th June 2024 at the symposium “Competencies in Drug Discovery” in Zurich, titled: “Strategic in silico pipeline for PROTAC screening: validation with CRBN-RN6-BRD4”.  We showcase our integrated computational & bioinformatics pipeline-guided evaluation of therapeutic targets and design of PROTAC molecules with emphasis on linker chemistry. PROTACs are the hottest therapeutic modalities to tackle undruggable targets where SMs fail to show the expected therapeutic outcome. BRD4 is a classic example of a potential anti-cancer target; PROTAC-mediated targeting of BRD4 has proven beneficial over SMs. Our pipeline aids in the identification of an optimal preclinical model for efficacy and safety/tox study. We provide a way forward in predicting the impact of deubiquitinating to estimate the therapeutic area-specific efficacy of the designed PROTACs.    We are excited to meet you at the poster session!  To download the poster,click: https://lnkd.in/gAEuSc5j     #ZHAW #Insilico #Bioinformatics #Cancer #PROTAC #DrugDiscovery #Integratedpipeline #TCGLifeSciences #DataScience #BRD4 #DUB #Efficacy #Toxicity    Sohini Basu, Snigdha Patel, Nivedita Dharwar, Anupama Goyal, Sonali Das, Joaquim Figueiredo

Network Medicines™ are a new class of therapeutic with the potential to transform the treatment of complex diseases that are driven by multicellular networks, such as #cancer and #fibrosis. They are designed to have both a direct effect by targeting diseased cells themselves and a network effect by reprogramming diseased cells to release therapeutic signals that coordinate other key cells in the network to restore health. Read more about Network Medicines as well as some of the other new science being pioneered by fellow #FlagshipFounded companies below. 

Antibody-conjugated oligonucleotides are revolutionizing the field of genetic medicine with improvements in selectivity, targetability, and overall safety profiles. However, the unique mechanisms of action for these novel modalities present additional challenges and considerations for safety assessment. Join co-chairs Sheroy Minocherhomji and Eileen Blasi to review case studies, discuss unique technical challenges, and learn safety development strategies for these novel oligonucleotide therapeutics in Symposium S08 at ACT's 2024 Annual Meeting titled "Hitching a Ride to Transduce Barriers: Nonclinical Safety Considerations for Developing Transcriptome Modulating Therapies". Link for registration to the Annual meeting: lnkd.in/ek5UQRza

Exciting news in AI-driven drug development! Iambic Therapeutics, an innovative AI biotech, is advancing into clinical trials with a focus on HER2 cancers. Their cutting-edge approach showcases yet another way in which AI-driven platforms will revolutionize healthcare. #AI #HealthcareInnovation #DrugDevelopment #PrecisionMedicine